The geptrong pharmaceutical product increases efficiency of postreplication repair of permutation intermediates in yeast Saccharomyces cerevisiae

Geptrong is a medication from pure defermentated honey. In medical practice, it is used as hepatoprotector. Genotoxicity analysis revealed antimutagenic activity of the preparation. The spontaneous mutation rate at the ADE4-ADE8 and CAN1 loci was several times lower in case that the yeast cells were plated on the geptrong-containing medium, and the mutation rate was scored using the method of ordered plating. If spontaneous mutation rate was measured by means of the fluctuation method of median, no antimutagenic activity was detected. Geptrong had no effect on the yeast cell survival. At the same time, it substantially decreased the frequency of direct mutations at the ADE4-ADE8 locus, induced by UV-and gamma-radiation, and ethylmetansulfonate. The effect of the geptrong antimutagenic activity on the level of UV-induced mutagenesis in the yeast strains defective for the repair systems rad2, rad51, rad54, rad59, msh2, and hsm3 was examined. Antimutagenic activity was detected in the wild type, as well as in the rad2, rad54, rad59, and hsm3 strains, while rad51, pms1, and msh2 mutants lacked this activity. Based on these data, it is suggested that antimutagenic effect of geptrong is associated with activated repair of mismatches, appeared during the postreplicative recombination repair.